血清KIM-1与β2微球蛋白预测2型糖尿病肾功能快速下降
在三个2型糖尿病队列中评估血清生物标志物组合对肾功能下降的预测价值。KIM-1与B2M联合临床因素可适度改善预测,曲线下面积分别提高0.079、0.073和0.239,更大组合未进一步改善预测。
要点
- KIM-1与B2M单独均与eGFR下降显著相关,标准化OR≥1.4(p<0.0003)。
- B2M+KIM-1联合临床因素可适度改善预测,不同队列AUC提高0.073–0.239。
- 增加更多Luminex标志物或质谱组合未能在所有验证集中进一步改善预测。
核心结论
- 血清KIM-1和B2M可独立于临床因素及基线eGFR和蛋白尿改善对2型糖尿病肾功能下降的预测。
- 更大组合的生物标志物未能超越这两个标志物的预测性能。
研究设计与样本
- 研究纳入657份来自SDR和GoDARTS的血清样本及183例来自CARDS的嵌套病例对照样本。
- 分析42种生物标志物,其中21种Luminex标志物在CARDS样本中检测。
- 事件定义为随访期间eGFR较基线下降>20%,基线eGFR为30-75 ml min-1 [1.73 m]-2。
- 中位随访7年,共403例发生事件,采用离散时间逻辑回归模型及十折交叉验证。
主要发现
- KIM-1和B2M在所有队列中效应最一致,标准化OR≥1.4(p<0.0003)。
- B2M+KIM-1联合临床因素使SDR、Go-DARTS和CARDS的AUC分别提高0.079、0.073和0.239。
- 在B2M和KIM-1基础上增加其他Luminex标志物、稀疏质谱组合或更大组合未能在所有验证集中一致改善预测。
临床怎么用
- 在2型糖尿病基线eGFR 30-75 ml min-1 [1.73 m]-2的患者中,可考虑检测血清KIM-1和B2M辅助预测肾功能下降风险。
- 临床因素、基线eGFR和蛋白尿仍是基础评估,KIM-1和B2M可提供额外预测信息。
局限性
- 样本储存条件不同,但KIM-1和B2M表现稳健。
- 研究为观察性队列及嵌套病例对照设计,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: As part of the Surrogate Markers for Micro- and Macrovascular Hard Endpoints for Innovative Diabetes Tools (SUMMIT) programme we previously reported that large panels of biomarkers derived from three analytical platforms maximised prediction of progression of renal decline in type 2 diabetes. Here, we hypothesised that smaller (n ≤ 5), platform-specific combinations of biomarkers selected from these larger panels might achieve similar prediction performance when tested in three additional type 2 diabetes cohorts. METHODS: We used 657 serum samples, held under differing storage conditions, from the Scania Diabetes Registry (SDR) and Genetics of Diabetes Audit and Research Tayside (GoDARTS), and a further 183 nested case-control sample set from the Collaborative Atorvastatin in Diabetes Study (CARDS). We analysed 42 biomarkers measured on the SDR and GoDARTS samples by a variety of methods including standard ELISA, multiplexed ELISA (Luminex) and mass spectrometry. The subset of 21 Luminex biomarkers was also measured on the CARDS samples. We used the event definition of loss of >20% of baseline eGFR during follow-up from a baseline eGFR of 30-75 ml min-1 [1.73 m]-2. A total of 403 individuals experienced an event during a median follow-up of 7 years. We used discrete-time logistic regression models with tenfold cross-validation to assess association of biomarker panels with loss of kidney function. RESULTS: Twelve biomarkers showed significant association with eGFR decline adjusted for covariates in one or more of the sample sets when evaluated singly. Kidney injury molecule 1 (KIM-1) and β2-microglobulin (B2M) showed the most consistent effects, with standardised odds ratios for progression of at least 1.4 (p < 0.0003) in all cohorts. A combination of B2M and KIM-1 added to clinical covariates, including baseline eGFR and albuminuria, modestly improved prediction, increasing the area under the curve in the SDR, Go-DARTS and CARDS by 0.079, 0.073 and 0.239, respectively. Neither the inclusion of additional Luminex biomarkers on top of B2M and KIM-1 nor a sparse mass spectrometry panel, nor the larger multiplatform panels previously identified, consistently improved prediction further across all validation sets. CONCLUSIONS/INTERPRETATION: Serum KIM-1 and B2M independently improve prediction of renal decline from an eGFR of 30-75 ml min-1 [1.73 m]-2 in type 2 diabetes beyond clinical factors and prior eGFR and are robust to varying sample storage conditions. Larger panels of biomarkers did not improve prediction beyond these two biomarkers.
引用
- Colombo M, Looker HC, Farran B, et al. Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. Diabetologia. 2018. PMID: 30288572. doi:10.1007/s00125-018-4741-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。